# Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas

> **NCT03021057** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 33 (estimated)

## Conditions studied

- T-Cell Lymphoma
- NK-Cell Lymphoma

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT03021057
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-01
- **Primary completion:** 2020-06
- **Final completion:** 2020-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2019-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03021057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03021057, "Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03021057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*